205 related articles for article (PubMed ID: 22884539)
1. Are major reductions in new HIV infections possible with people who inject drugs? The case for low dead-space syringes in highly affected countries.
Zule WA; Cross HE; Stover J; Pretorius C
Int J Drug Policy; 2013 Jan; 24(1):1-7. PubMed ID: 22884539
[TBL] [Abstract][Full Text] [Related]
2. Factors that influence the characteristics of needles and syringes used by people who inject drugs in Tajikistan.
Zule WA; Latypov A; Otiashvili D; Kirtadze I; Ibragimov U; Bobashev GV
Harm Reduct J; 2015 Oct; 12():37. PubMed ID: 26472669
[TBL] [Abstract][Full Text] [Related]
3. Low dead-space syringes for preventing HIV among people who inject drugs: promise and barriers.
Zule WA
Curr Opin HIV AIDS; 2012 Jul; 7(4):369-75. PubMed ID: 22627710
[TBL] [Abstract][Full Text] [Related]
4. Could low dead-space syringes really reduce HIV transmission to low levels?
Vickerman P; Martin NK; Hickman M
Int J Drug Policy; 2013 Jan; 24(1):8-14. PubMed ID: 23206493
[TBL] [Abstract][Full Text] [Related]
5. Low Dead-Space Syringes for HIV prevention among people who inject drugs: interesting, but a much stronger case is required.
Ambekar A; Pawar A
Int J Drug Policy; 2013 Jan; 24(1):16-8. PubMed ID: 23127665
[No Abstract] [Full Text] [Related]
6. Social marketing of low dead space syringes in Vietnam: findings from a 1-year pilot program in Hanoi, Thai Nguyen, and Ho Chi Minh City.
Huong NT; Mundy G; Neukom J; Zule W; Tuan NM; Tam NM
Harm Reduct J; 2015 May; 12():15. PubMed ID: 26024921
[TBL] [Abstract][Full Text] [Related]
7. Options for reducing HIV transmission related to the dead space in needles and syringes.
Zule WA; Pande PG; Otiashvili D; Bobashev GV; Friedman SR; Gyarmathy VA; Des Jarlais DC
Harm Reduct J; 2018 Jan; 15(1):3. PubMed ID: 29334973
[TBL] [Abstract][Full Text] [Related]
8. Detachable low dead space syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an economic evaluation.
Hancock E; Ward Z; Ayres R; Neale J; Hussey D; Kesten JM; Hickman M; Vickerman P
Addiction; 2020 Apr; 115(4):702-713. PubMed ID: 31633849
[TBL] [Abstract][Full Text] [Related]
9. Implementation of low dead-space syringes needs consultation and engagement with drug users.
Albers ER
Int J Drug Policy; 2013 Jan; 24(1):19-20. PubMed ID: 23127667
[No Abstract] [Full Text] [Related]
10. Acceptability of low dead space syringes and implications for their introduction: A qualitative study in the West of England.
Kesten JM; Ayres R; Neale J; Clark J; Vickerman P; Hickman M; Redwood S
Int J Drug Policy; 2017 Jan; 39():99-108. PubMed ID: 27788406
[TBL] [Abstract][Full Text] [Related]
11. Low dead space syringes: authors' response.
Zule WA; Cross HE; Stover J; Pretorius C
Int J Drug Policy; 2013 Jan; 24(1):21-2. PubMed ID: 23246189
[No Abstract] [Full Text] [Related]
12. How to encourage use of low dead space syringes? The Viet Nam experience.
Jacka D
Int J Drug Policy; 2013 Jan; 24(1):18-9. PubMed ID: 23122053
[No Abstract] [Full Text] [Related]
13. Saying goodbye to high-dead-space syringes.
Ciccarone D
Int J Drug Policy; 2013 Jan; 24(1):15-6. PubMed ID: 23127666
[No Abstract] [Full Text] [Related]
14. Co-design of harm reduction materials for people who inject drugs to implement research findings.
Hussey D; Trinder-Widdess Z; Dee C; Bagnall D; Bojangles T; Kesten JM
Harm Reduct J; 2019 Jun; 16(1):36. PubMed ID: 31174536
[TBL] [Abstract][Full Text] [Related]
15. Service utilization and cost of implementing a comprehensive HIV prevention and care program among people who inject drugs in Delhi, India.
Sebastian MP; Dasgupta A; Saraswati LR; Singh A; Sharma V; Madan I; Tun W; Pulerwitz J; Thior I; Sarna A
Harm Reduct J; 2017 Jun; 14(1):38. PubMed ID: 28615077
[TBL] [Abstract][Full Text] [Related]
16. Using Pharmacies in a Structural Intervention to Distribute Low Dead Space Syringes to Reduce HIV and HCV Transmission in People Who Inject Drugs.
Oramasionwu CU; Johnson TL; Zule WA; Carda-Auten J; Golin CE
Am J Public Health; 2015 Jun; 105(6):1066-71. PubMed ID: 25880955
[TBL] [Abstract][Full Text] [Related]
17. Dead space: a risk factor we did not see.
Preston A
Int J Drug Policy; 2013 Jan; 24(1):20. PubMed ID: 23127663
[No Abstract] [Full Text] [Related]
18. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States.
Holtgrave DR; Pinkerton SD; Jones TS; Lurie P; Vlahov D
J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 18 Suppl 1():S133-8. PubMed ID: 9663636
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of needle and syringe programs in Tajikistan distributing low dead space needles.
Zule WA; Latypov A; Otiashvili D; Bangel S; Bobashev GV
Harm Reduct J; 2018 Aug; 15(1):44. PubMed ID: 30170604
[TBL] [Abstract][Full Text] [Related]
20. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Strathdee SA; Nosyk B;
J Infect Dis; 2020 Sep; 222(Suppl 5):S301-S311. PubMed ID: 32877548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
